Systems neuropharmacology of nicotine in aversive learning in humans - NICO3

Institut für Systemische Neurowissenschaften0 个研究点目标入组 88 人开始时间: 2022年2月7日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. past or present illnesses of the
•- Brain or mind (incl. anxiety disorders, depression, schizophrenia, alcohol, drug or medication dependence, neurological disorders other than occasional headaches),
•- Heart or circulatory system (incl. hypertension),
•- kidneys,
•- thyroid gland,
•- Eyes (including glaucoma, color blindness, and myopia greater than -5 diopters),
•- gastrointestinal tract,
•- metabolism.
•It does not matter whether the disease is treated or untreated, was long or short term, or dates back a long time. This does not include former childhood illnesses and former harmless illnesses such as common gastrointestinal infections, stress headaches, colds, etc.
•2. cancer.
•3. hypersensitivity to nicotine.
•4. current medication and medication in a period of 2 months before treatment. Only over-the-counter medications are excluded if their intake dates back more than 1 week before participation in the study.
•5. other serious health problems or current severe mental or physical stress.
•6. having metallic objects in or on the body that cannot be removed.
•7. cigarette consumption of less than 1 cigarette in lifetime (never-smoker).

发起方

Institut für Systemische Neurowissenschaften